Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's
formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation
(Plavix® 300 mg tablets) in healthy, adult, human, male subjects under fasting conditions and
to assess the bioequivalence.